Telomir Pharmaceuticals closes $5.6 million PIPE as DeJoria adds to stake

Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) announced on October 6, 2026 that it closed a private investment in public equity financing of common stock worth approximately $5.6 million. The financing was structured as a common stock PIPE without any accompanying investor warrants or convertible securities.¹

The closing occurred on October 5, 2026, under a securities purchase agreement in which Telomir sold 4,843,300 shares of common stock to a group of investors.¹ The purchase price was $1.16 per share, a 5% discount to the 10-day volume-weighted average price of the stock on the Nasdaq Capital Market ending two days before closing.¹

Investors included John Paul DeJoria, an existing significant shareholder, who put in an additional $1.0 million.¹ DeJoria most recently reported beneficial ownership of approximately 3.55 million shares, about 5.0% of Telomir's outstanding common stock.¹

Alexander Capital, L.P. served as placement agent under a June 25, 2026 engagement letter and will receive a cash fee equal to 9.0% of gross proceeds, approximately $455,000.¹ The company also issued Alexander Capital warrants to purchase 387,464 shares, representing 8.0% of the shares sold, at an exercise price of $1.16 per share, exercisable for cash with a five-year term.¹ Telomir agreed to file a resale registration statement with the SEC within 30 days of closing.¹

Proceeds are intended primarily to support clinical development of Telomir-Zn, including the company's Phase 1/2 program in advanced or metastatic triple-negative breast cancer, plus working capital and general corporate purposes.¹ The FDA has cleared Telomir's IND for Telomir-Zn, allowing the company to proceed with its first-in-human Phase 1/2 trial in that patient population.¹ The multicenter, open-label study is designed to move from initial dosing through dose selection in Phase 1, assessing safety, tolerability and pharmacodynamic biomarkers, before an efficacy-focused Phase 2 expansion intended as an initial proof-of-concept assessment.¹